Resmed Inc. Stock
Resmed Inc. Stock
The price for the Resmed Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.900 (-0.420%).
With 22 Buy predictions and not a single Sell prediction Resmed Inc. is an absolute favorite of our community.
With a target price of 259 € there is a positive potential of 20.52% for Resmed Inc. compared to the current price of 214.9 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | -0.420% | -2.451% | -1.557% | -7.251% | -3.329% | 2.480% | 27.160% |
| Veeva Systems A | -2.530% | -8.494% | -25.810% | -14.424% | -6.422% | 16.328% | -12.755% |
| Thermo Fisher Scientific Inc. | -1.250% | -0.885% | -3.923% | -2.812% | -2.393% | -9.506% | 25.280% |
| Waters Corp. | -2.270% | -1.851% | -0.090% | -8.541% | -6.046% | 4.504% | 67.889% |
Comments
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
